Internet Explorer does not cooperate with this site. Please see below for options that work with APNA eLearning. *

404-23: New Mechanisms in the Pipeline for Treating Persons with Schizophrenia: Is it Really Different this Time?

Understand the implications of knowing that direct dopamine receptor affinity is not always necessary for antipsychotic efficacy, and explore how to get ready for new therapies that might be available in the not-too-distant future.

Presenter:  Peter J. Weiden, MD

Disclosures:  The APNA planners and faculty, with the exception of those listed below, have no relevant financial relationships to disclose. All relevant financial relationships listed for these individuals have been mitigated. Off-label uses will be discussed during this presentation.

Dr. Peter J. Weiden, MD, is a consultant for Alkermes Inc., and Lyndra Therapeutics. Dr. Weiden was an employee of Karuna Therapeutics (this relevant financial relationship has been divested).

Session Length:  1 hour 15 minutes

Target Audience:  RN, APRN

Learning Outcome:
Upon completion of this presentation, the participant will be able to:

• Identify new and emerging treatments for schizophrenia.

Keywords:  Schizophrenia, Antipsychotics, Dopamine, Receptor, Neuroscience

Nursing Continuing Professional Development:
1.25 pharmacology contact hours.  * In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and earn a passing score on the post-test before the expiration date. You will have 5 tries to correctly answer the questions on the post-test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

The American Psychiatric Nurses Association is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Access to this course will end: July 31, 2025

*For an uninterrupted learning experience, please download and use Google Chrome, Mozilla Firefox, Microsoft Edge, Safari, etc. If you continue to experience issues, you may need to update your browser.